Skip to main content
TipRanks
Go Ultimate75% OFF

Edwards Lifesciences (0REN) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Edwards Lifesciences has a market cap or net worth of CHF 51.70B. The enterprise value is CHF 46.02B.

Market Cap
CHF 51.70B
Enterprise Value
CHF 46.02B

Share Statistics

Edwards Lifesciences has 575,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
575,000,000
Owned by Insiders
0.20%
Owned by Institutions
74.78%

Financial Efficiency

Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.

Return on Equity (ROE)
0.10
Return on Assets (ROA)
0.08
Return on Invested Capital (ROIC)
11.40%
Return on Capital Employed (ROCE)
0.14
Revenue Per Employee
379.23K
Profits Per Employee
67.09K
Employee Count
16,000
Asset Turnover
0.44
Inventory Turnover
1.18

Valuation Ratios

The current PE Ratio of Edwards Lifesciences is 60.54. Edwards Lifesciences’s PEG ratio is -2.52.

PE Ratio
60.54
PS Ratio
9.23
PB Ratio
5.69
Price to FCF
43.26
Price to Operating Cash Flow
35.97
PEG Ratio
-2.52

Income Statement

In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.

Revenue
6.07B
Gross Profit
4.74B
Operating Income
1.64B
Pretax Income
1.27B
Net Income
1.07B
EBITDA
1.43B
Earnings Per Share (EPS)
1.84

Cash Flow

In the last 12 months, operating cash flow was 1.72B and capital expenditures -292.80M, giving a free cash flow of 1.42B billion.

Operating Cash Flow
1.72B
Free Cash Flow
1.42B
Free Cash Flow per Share
2.47

Dividends & Yields

Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
2.31%
Earnings Yield
1.65%

Important Dates

Edwards Lifesciences upcoming earnings date is Jan 27, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Jan 27, 2027
Ex-Dividend Date
―

Financial Position

Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.82%

Current Ratio
3.72
Quick Ratio
3.09
Debt to Market Cap
0.01
Net Debt to EBITDA
-1.56
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.

Income Tax
216.90M
Effective Tax Rate
0.17

Enterprise Valuation

Edwards Lifesciences EV to EBITDA ratio is 36.93, with an EV/FCF ratio of 41.57.

EV to Sales
8.87
EV to EBITDA
36.93
EV to Free Cash Flow
41.57
EV to Operating Cash Flow
34.48

Balance Sheet

Edwards Lifesciences has CHF 4.64B in cash and marketable securities with CHF 704.50M in debt, giving a net cash position of CHF 3.94B billion.

Cash & Marketable Securities
CHF 4.64B
Total Debt
CHF 704.50M
Net Cash
CHF 3.94B
Net Cash Per Share
CHF 6.85
Tangible Book Value Per Share
CHF 13.62

Margins

Gross margin is 78.13%, with operating margin of 25.52%, and net profit margin of 15.30%.

Gross Margin
78.13%
Operating Margin
25.52%
Pretax Margin
21.46%
Net Profit Margin
15.30%
EBITDA Margin
24.02%
EBIT Margin
21.46%

Analyst Forecast

The average price target for Edwards Lifesciences is CHF 96.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
CHF 96.42
Price Target Upside
―
Analyst Consensus
Strong Buy
Analyst Count
23
Revenue Growth Forecast
6.41%
EPS Growth Forecast
-31.90%

Scores

Smart Score
8
AI Score
―